TREATMENT OF IRRITABLE BOWEL SYNDROME: A REVIEW
DOI:
https://doi.org/10.22159/ajpcr.2018.v11i9.25953Keywords:
Irritable bowel syndrome, Symptoms, Treatment, Alternative treatment, Alter medicineAbstract
Irritable bowel syndrome (IBS) is a gastrointestinal disease which is also called as spastic colon, mucous colitis is characterized by some non-specific symptoms, such as altered bowel habits and abdominal pain, stomach bloating, chronic diarrhea or constipation or alternating between the two. The therapy is based on the healing of symptoms using various pharmaceutical and non-pharmaceutical agents. The objective of treatment is relief from symptom and improved quality of life. The approach for the treatment of IBS is based on the predominant symptoms of the patient. Classical as well as alternative treatment, both appear to be effective for the patients. Classical treatments basically consist of antidiarrheal, antidepressants, antispasmodic, bulking agents, osmotic laxatives, etc. Still, herbal or alternative treatment always seems to be the same beneficiary for the patients due to their negligible adverse effect.
Downloads
References
Sameer A, Faisal A, Abdullah A, Ahmad B, Abdulaziz A, Abdulrahman A, et al. A study of impact and prevalence of irritable bowel syndrome among medical students. Int J Med Med Sci 2015;7:139-47.
Chey WD, Kurlander ES. Irritable bowel syndrome: A clinical review. JAMA 2015;313:949-58.
Quigley EM, Abdel HH, Barbara GB, Boeckxstaens SJ, Giorgio G, Delvaux R, et al. A global perspective on irritable bowel syndrome: A consensus statement of the world gastroenterology organization summit task force on irritable bowel syndrome. J Clin Gastroenterol 2001;46:356-66.
Chang L, Lembo A, Sultan S. American gastroenterological association institute technical review on the pharmacological management of irritable bowel syndrome. Gastroenterology 2014;147:1149-7200.
Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: A meta-analysis. Clin Gastroenterol Hepatol 2012;10:712-210000.
Chang FY, Chen CL. The current prevalence of irritable bowel syndrome in Asia. J Neurogastroenterol Motil 2010;16:389-400.
Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC, et al. Functional bowel disorders. Gastroenterology 2006;130:1480-91.
Horwitz BJ, Fisher RS. The irritable bowel syndrome. World J Gastroenterol 2014;20:12144-60.
Makharia GK, Verma AK, Amarchand R, Goswami A, Singh P, Agnihotri A, et al. Prevalence of irritable bowel syndrome: A community based study from northern India. J Neurogastroenterol Motil 2011;17:82-7.
Barbara G, Dolci M, Cremon C, Barbora MR, Bellacosa L, Fucili A, et al. Understanding the pathophysiology of IBS. Eur Med J Gastroenterol 2013;1:40-6.
Crowell MD. The role of serotonin in the pathophysiology of irritable bowel syndrome. Am J Manag Care 2001;7:S252-60.
Jose S, Dhanya K, Cinu TA, Aleykutty NA. Multiparticulate system for colon targeted delivery of ondansetron. Indian J Pharm Sci 2010;72:58-64.
De Ponti F. Pharmacology of serotonin: What a clinician should know. Gut 2004;53:1520-35.
Kassinen A, Krogius-Kurikka L, Mäkivuokko H, Rinttilä T, Paulin L, Corander J, et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology 2007;133:24-33.
Spiller R. Review article: Probiotics and prebiotics in irritable bowel syndrome. Aliment Pharmacol Ther 2008;28:385-96.
Christina W, Susan P. Prebiotics and Probiotics for Prevention of Allergic Disease. Waltham: UpToDate; 2011.
Derbyshire SW. A systematic review of neuroimaging data during visceral stimulation. Am J Gastroenterol 2003;98:12-20.
Bijkerk CJ, Muris JW, Knottnerus JA, Hoes AW, de Wit NJ. Systematic review: The role of different types of fibre in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2004;19:245-51.
Ford AC, Talley NJ, Spiegel BM, Foxx-Orenstein AE, Schiller L, Quigley EM, et al. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: Systematic review and meta-analysis. BMJ 2008;337:a2313.
Johnson ME, Johnson JL. Management of slow colonic transit constipation in Parkinson’s disease: Current evidence and a community pharmacy perspective. Int J Pharm Pharm Sci 2016;8:28-34.
Chandira RM, Bhowmik D, Jayakar CB. Formulation and evaluation of gastroretentive drug delivery system of gastroprokinetic drug itopride hydrochloride. Int J Pharm Pharm Sci 2010;2:53-65.
Spiller R. Serotonergic modulating drugs for functional gastrointestinal diseases. Br J Clin Pharmacol 2002;54:11-20.
Grider JR, Foxx-Orenstein AE, Jin JG 5-hydroxytryptamine4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestine. Gastroenterology 1998;115:370-80.
Prather CM, Camilleri M, Zinsmeister AR, McKinzie S, Thomforde G. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology 2000;118:463-8.
Khoshoo V, Armstead C, Landry L. Effect of a laxative with and without tegaserod in adolescents with constipation predominant irritable bowel syndrome. Aliment Pharmacol Ther 2006;23:191-6.
Cherian S, Anitha S. Study of the prescribing pattern of probiotics in paediatric patients of a tertiary care teaching hospital, South India. Int J Pharm Pharm Sci 2012;4:505-8.
Lembo T, Wright RA, Bagby B, Decker C, Gordon S, Jhingran P, et al. Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2001;96:2662-70.
Das RR, Singh M, Nusrat S. Probiotics for prevention or treatment of asthma. Pediatr Asthma Posters 2017 ;???:???.
Salman FZ, Ferreira NL, Enoch B, Tina WU, Kecia C, William PF, et al. T1411 Predictors of clinical response from a phase 2 multi center efficacy trial using rifaximin, a gut-selective, nonabsorbed antibiotic for the treatment of diarrhea-associated Irritable bowel syndrome. Gastroenterology 2008;134:545-50
Lembo A, Zakko SF, Ferreira NL. Rifaximin for the treatment of diarrhea associated irritable bowel syndrome: Short term treatment leading to long term sustained response. Clin Exp Gastroenterol 2012;5:69-100.
Pimentel M, Park S, Mirocha J, Kane SV, Kong Y. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: A randomized trial. Ann Intern Med 2006;145:557-63.
Coleman N, Spiller R. New pharmaceutical approaches to the treatment of IBS: Future development and research. Ann Gasteroenterol 2002;15:278-89.
Mueller-Lissner S, Tytgat GN, Paulo LG, Quigley EM, Bubeck J, Peil H, et al. Placebo- and paracetamol-controlled study on the efficacy and tolerability of hyoscine butylbromide in the treatment of patients with recurrent crampy abdominal pain. Aliment Pharmacol Ther 2006;23:1741-8.
Ritchie JA, Truelove SC. Treatment of irritable bowel syndrome with lorazepam, hyoscine butylbromide, and ispaghula husk. Br Med J 1979;1:376-8.
Lacy BE, Kirsten W, Lee RD. The treatment of irritable bowel syndrome. Ther Adv Gastroenterol 2009;2:221-38.
Mayer EA, Berman S, Derbyshire SW, Suyenobu B, Chang L, Fitzgerald L, et al. The effect of the 5-HT3 receptor antagonist, alosetron, on brain responses to visceral stimulation in irritable bowel syndrome patients. Aliment Pharmacol Ther 2002;16:1357-66.
Camilleri M, Chey WY, Mayer EA, Northcutt AR, Heath A, Dukes GE, et al. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch Intern Med 2001;161:1733-40.
Camilleri M, Kerstens R, Rykx A, Vandeplassche L. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med 2008;358:2344-54.
Rivkin A, Rybalov S. Update on the management of diarrhea-predominant irritable bowel syndrome: Focus on rifaximin and eluxadoline. Pharmacotherapy 2016;36:300-16.
Clouse RE, Lustman PJ. Use of psychopharmacological agents for functional gastrointestinal disorders. Gut 2005;54:1332-41.
Drossman DA, Morris CB, Schneck S, Hu YJ, Norton NJ, Norton WF, et al. International survey of patients with IBS: Symptom features and their severity, health status, treatments, and risk taking to achieve clinical benefit. J Clin Gastroenterol 2009;43:541-50.
Drossman DA. Beyond tricyclics: New ideas for treating patients with painful and refractory functional gastrointestinal symptoms. Am J Gastroenterol 2009;104:2897-902.
Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011;364:22-32.
Lembo AJ, Brian E, Lacy MJ, Schey R, Dove LS, David AA, et al. Eluxadoline for irritable bowel syndrome with diarrhea. N Engl J Med 2016;374:242-53.
Davenport JM, Covington P, Bonifacio L, McIntyre G, Venitz J. Effect of uptake transporters OAT3 and OATP1B1 and efflux transporter MRP2 on the pharmacokinetics of eluxadoline. J Clin Pharmacol 2015;55:534-42.
Drossman DA, Chey WD, Johanson JF, Fass R, Scott C, Panas R, et al. Clinical trial: Lubiprostone in patients with constipation-associated irritable bowel syndrome – results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther 2009;29:329-41.
Bryant AP, Busby RW, Bartolini WP, Cordero EA, Hannig G, Kessler MM, et al. Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract. Life Sci 2010;86:760-5.
Andresen V, Camilleri M, Busciglio IA, Grudell A, Burton D, McKinzie S, et al. Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome. Gastroenterology 2007;133:761-8.
Lacy BE, Levy LC. Lubiprostone: A novel treatment for chronic constipation. Clin Interv Aging 2008;3:357-64.
Barish CF, Drossman D, Johanson JF, Ueno R. Efficacy and safety of lubiprostone in patients with chronic constipation. Dig Dis Sci 2010;55:1090-7.
Johnston JM, Kurtz CB, Macdougall JE, Lavins BJ, Currie MG, Fitch DA, et al. Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation. Gastroenterology 2010;139:1877-8600.
American College of Gastroenterology Task Force on Irritable Bowel Syndrome, Brandt LJ, Chey WD, Foxx-Orenstein AE, Schiller LR, Schoenfeld PS, et al. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009;104 Suppl 1:S1-35.
Chey WD, Lembo AJ, Lavins BJ, Shiff SJ, Kurtz CB, Currie MG, et al. Linaclotide for irritable bowel syndrome with constipation: A 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol 2012;107:1702-12.
Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology 2002;123:2108-31.
Somers SC, Lembo A. Irritable bowel syndrome: Evaluation and treatment. Gastroenterol Clin North Am 2003;32:507-29.
Brandt LJ, Bjorkman D, Fennerty MB, Locke GR, Olden K, Peterson W, et al. Systematic review on the management of irritable bowel syndrome in North America. Am J Gastroenterol 2002;97:S7-26.
Lembo T, Rink R. Current pharmacologic treatments of irritable bowel syndrome. participate (international foundation for functional gastrointestinal disorders). N Engl J Med 2002;11:1-4.
Berrada D, Canenguez K, Lembo T. New approaches to the medical treatment of irritable bowel syndrome. Curr Gastroenterol Rep 2003;5:337-42.
Camilleri M. Review article: Clinical evidence to support current therapies of irritable bowel syndrome. Aliment Pharmacol Ther 1999;13 Suppl 2:48-53.
Ahn J, Ehrenpreis ED. Emerging treatments for irritable bowel syndrome. Expert Opin Pharmacother 2002;3:9-21.
Camilleri M. Novel pharmacology: Asimadoline, a kappa-opioid agonist, and visceral sensation. Neurogastroenterol Motil 2008;20:971-9.
Shekhar C, Whorwell PJ. Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs 2009;14:673-85.
Delgado-Aros S, Chial HJ, Cremonini F, Ferber I, McKinzie S, Burton DD, et al. Effects of asimadoline, a kappa-opioid agonist, on satiation and postprandial symptoms in health. Aliment Pharmacol Ther 2003;18:507-14.
Grigoleit HG, Grigoleit P. Pharmacology and preclinical pharmacokinetics of peppermint oil. Phytomedicine 2005;12:612-6.
Hawthorn M, Ferrante J, Luchowski E, Rutledge A, Wei XY, Triggle DJ, et al. The actions of peppermint oil and menthol on calcium channel dependent processes in intestinal, neuronal and cardiac preparations. Aliment Pharmacol Ther 1988;2:101-18.
Amato A, Liotta R, Mulè F. Effects of menthol on circular smooth muscle of human colon: Analysis of the mechanism of action. Eur J Pharmacol 2014;740:295-301.
Liu JH, Chen GH, Yeh HZ, Huang CK, Poon SK. Enteric-coated peppermint-oil capsules in the treatment of irritable bowel syndrome: A prospective, randomized trial. J Gastroenterol 1997;32:765-8.
Pittler MH, Ernst E. Peppermint oil for irritable bowel syndrome: A critical review and metaanalysis. Am J Gastroenterol 1998;93:1131-5.
Hills JM, Aaronson PI. The mechanism of action of peppermint oil on gastrointestinal smooth muscle. An analysis using patch clamp electrophysiology and isolated tissue pharmacology in rabbit and guinea pig. Gastroenterology 1991;101:55-65.
Gilani AH, Shah AJ, Ghayur MN, Majeed K. Pharmacological basis for the use of turmeric in gastrointestinal and respiratory disorders. Life Sci 2005;76:3089-105.
Ghayur MN, Gilani AH. Pharmacological basis for the medicinal use of ginger in gastrointestinal disorders. Dig Dis Sci 2005;50:1889-97.
Lemberkovics E, Kéry A, Marczal G, Simándi B, Szöke E. Phytochemical evaluation of essential oils, medicinal plants and their preparations. Acta Pharm Hung 1998;68:141-9.
Kala C, Ali SS, Chaudhary S. Comparative pharmacognostical evaluation af Costus speciosus (Wild Ginger) and Zingiber officinale (Ginger) rhizome. Int J Curr Pharm Res 2016;8:19-23.
Carnat A, Carnat AP, Fraisse D, Ricoux L, Lamaison JL. The aromatic and polyphenolic composition of roman camomile tea. Fitoterapia 2004;75:32-8.
Sakai H, Misawa M. Effect of sodium azulene sulfonate on capsaicin-induced pharyngitis in rats. Basic Clin Pharmacol Toxicol 2005;96:54-9.
Pena D, Montes de Oca N, Rojas S. Anti-inflammatory and anti-diarrheic activity of Isocarpha cubana Blake. Pharmacologyonline 2006;3:744-9.
Kroll U, Cordes C. Pharmaceutical prerequisites for a multi-target theray. Phytomedicine 2006;5:12-9.
Akram M, Siddiqui MI, Akhter N, Waqas MK, Iqbal Z, Khan AA, et al. Herbal treatment of irritable bowel syndrome: A review. J Med Plants Res 2011;5:6934-8.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
